Clinical trial
A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy…
NCT00312767 · Genzyme, a Sanofi Company, Industry · Withdrawn
Key facts
| NCT number | NCT00312767 |
|---|---|
| Title | A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency. |
| Official title | A Multicenter, Open-Label, Cross-Over Trial to Evaluate the Pharmacokinetics of Fabrazyme During Simultaneous Fabrazyme Infusion and Chronic Hemodialysis in Patients With Fabry Disease. |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | Fabrazyme (agalsidase beta) |
| Enrollment | 0 |
| Start date | Apr 1, 2006 |
| First posted | Apr 11, 2006 |
| Last update posted | Feb 5, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: